Academic Journal
PS1121 ABSENCE OF GPI‐NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6‐MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA
| العنوان: | PS1121 ABSENCE OF GPI‐NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6‐MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA |
|---|---|
| المؤلفون: | Tjon, J., Bogers, L., de Wreede, L., de Groot, M., Langemeijer, S., Koene, H., Meijer, E., Nur, E., Raaijmakers, M., Raymakers, R., Snijders, T., Halkes, S. |
| المصدر: | HemaSphere ; volume 3, issue S1, page 507-508 ; ISSN 2572-9241 2572-9241 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2019 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Background: In aplastic anemia (AA), allogeneic stem cell transplantation (AlloSCT) is proposed as first line treatment for young patients with a sibling donor. For all other patients, ATGAM‐based immunosuppressive therapy (IST) is the treatment of choice. After IST, recovery of blood counts can take up to 6 months. Patients with (very) severe AA ((V)SAA), with a neutrophil count <0.2 or <0.5 x 10 9 /L respectively, remain at risk for infectious complications until blood count recovery. Timely identification of patients less likely to respond to IST could lead to earlier selection for second line treatment (either alloSCT or second line IST) in order to prevent prolonged neutropenia. In AA, the presence of glycophosphatidylinositol (GPI) negative cell clones at diagnosis is associated with a better response to IST in some studies. We hypothesized that the absence of GPI negative cells (<0.1%) before IST and low neutrophil count 2 months after start of treatment are associated with a lower response rate 6 months after IST in (V)SAA patients. Aims: To Determine whether the presence of GPI negative cell clones before IST and a neutrophil count <0.2 x 10 9 /L 2 months after IST can predict for treatment refractoriness at 6 months in adult (V)SAA patients. Methods: The Dutch registry of adults with acquired aplastic anemia receiving ATGAM (40 mg/kg for 4 days intravenously) and ciclosporin as first‐line treatment contains data on all consecutive patients treated in 8 major hospitals (LUMC, A‐UMC, UMCG, R‐UMC, UMCN, EMC, MST and AZN) including baseline and monthly follow‐up data. Response at 6 months was defined as transfusion independency and neutrophil count >0.5 x 10 9 /L. Overall survival (OS) was evaluated with the Kaplan‐Meier method. Results: Between 2012 and February 2019, 73 patients, 47 with SAA and 26 with VSAA were registered. Median age at start of IST was 58 years (18–79) and the median follow up time was 21 months. The 6‐month OS probability was 96% for SAA and VSAA combined (88% for VSAA ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1097/01.hs9.0000562768.31204.d4 |
| DOI: | 10.1097/01.HS9.0000562768.31204.d4 |
| الاتاحة: | http://dx.doi.org/10.1097/01.hs9.0000562768.31204.d4 https://onlinelibrary.wiley.com/doi/pdf/10.1097/01.HS9.0000562768.31204.d4 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.BE7A9DBC |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.BE7A9DBC 893 3 Academic Journal academicJournal 892.664306640625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.BE7A9DBC&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => http://dx.doi.org/10.1097/01.hs9.0000562768.31204.d4# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => PS1121 ABSENCE OF GPI‐NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6‐MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Tjon%2C+J%2E%22">Tjon, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Bogers%2C+L%2E%22">Bogers, L.</searchLink><br /><searchLink fieldCode="AR" term="%22de+Wreede%2C+L%2E%22">de Wreede, L.</searchLink><br /><searchLink fieldCode="AR" term="%22de+Groot%2C+M%2E%22">de Groot, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Langemeijer%2C+S%2E%22">Langemeijer, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Koene%2C+H%2E%22">Koene, H.</searchLink><br /><searchLink fieldCode="AR" term="%22Meijer%2C+E%2E%22">Meijer, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Nur%2C+E%2E%22">Nur, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Raaijmakers%2C+M%2E%22">Raaijmakers, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Raymakers%2C+R%2E%22">Raymakers, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Snijders%2C+T%2E%22">Snijders, T.</searchLink><br /><searchLink fieldCode="AR" term="%22Halkes%2C+S%2E%22">Halkes, S.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => HemaSphere ; volume 3, issue S1, page 507-508 ; ISSN 2572-9241 2572-9241 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Wiley Online Library (Open Access Articles via Crossref) ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: In aplastic anemia (AA), allogeneic stem cell transplantation (AlloSCT) is proposed as first line treatment for young patients with a sibling donor. For all other patients, ATGAM‐based immunosuppressive therapy (IST) is the treatment of choice. After IST, recovery of blood counts can take up to 6 months. Patients with (very) severe AA ((V)SAA), with a neutrophil count <0.2 or <0.5 x 10 9 /L respectively, remain at risk for infectious complications until blood count recovery. Timely identification of patients less likely to respond to IST could lead to earlier selection for second line treatment (either alloSCT or second line IST) in order to prevent prolonged neutropenia. In AA, the presence of glycophosphatidylinositol (GPI) negative cell clones at diagnosis is associated with a better response to IST in some studies. We hypothesized that the absence of GPI negative cells (<0.1%) before IST and low neutrophil count 2 months after start of treatment are associated with a lower response rate 6 months after IST in (V)SAA patients. Aims: To Determine whether the presence of GPI negative cell clones before IST and a neutrophil count <0.2 x 10 9 /L 2 months after IST can predict for treatment refractoriness at 6 months in adult (V)SAA patients. Methods: The Dutch registry of adults with acquired aplastic anemia receiving ATGAM (40 mg/kg for 4 days intravenously) and ciclosporin as first‐line treatment contains data on all consecutive patients treated in 8 major hospitals (LUMC, A‐UMC, UMCG, R‐UMC, UMCN, EMC, MST and AZN) including baseline and monthly follow‐up data. Response at 6 months was defined as transfusion independency and neutrophil count >0.5 x 10 9 /L. Overall survival (OS) was evaluated with the Kaplan‐Meier method. Results: Between 2012 and February 2019, 73 patients, 47 with SAA and 26 with VSAA were registered. Median age at start of IST was 58 years (18–79) and the median follow up time was 21 months. The 6‐month OS probability was 96% for SAA and VSAA combined (88% for VSAA ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1097/01.hs9.0000562768.31204.d4 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1097/01.HS9.0000562768.31204.d4 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://dx.doi.org/10.1097/01.hs9.0000562768.31204.d4<br />https://onlinelibrary.wiley.com/doi/pdf/10.1097/01.HS9.0000562768.31204.d4 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => http://onlinelibrary.wiley.com/termsAndConditions#vor ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.BE7A9DBC ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1097/01.hs9.0000562768.31204.d4
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => PS1121 ABSENCE OF GPI‐NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6‐MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tjon, J.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bogers, L.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de Wreede, L.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de Groot, M.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Langemeijer, S.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Koene, H.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Meijer, E.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nur, E.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Raaijmakers, M.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Raymakers, R.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Snijders, T.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Halkes, S.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => HemaSphere ; volume 3, issue S1, page 507-508 ; ISSN 2572-9241 2572-9241
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |